Elevance Health(DE:A58)
€383.00-7.60 (-1.95%)
DE:A58
Elevance Health stock forecast
€383.00
At close:-7.60 (-1.95%)
Elevance Health (A58) Stock Forecast & Price Target
3 Followers
A58 Analyst Ratings
Moderate Buy
9Buy5Hold0Sell
Based on 14 analysts giving stock ratings to Elevance Health in the past 3 months
A58 Stock 12 Month Forecast
Average Price Target
€427.56▲(11.64% Upside)Based on 14 Wall Street analysts offering 12 month price targets for Elevance Health in the last 3 months. The average price target is EUR 427.56 with a high forecast of EUR 466.01 and a low forecast of EUR 361.76. The average price target represents a 11.64% change from the last price of EUR 383.00.
Past 12 Months12 Month ForecastJan2026Oct2026
High€466.01
Average€427.56
Low€361.76
Highest Price TargetHighest€466.01Average Price Target€427.56Lowest Price TargetLowest€361.76
Detailed List of Analyst Forecasts​
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| Lance Wilkes | Bernstein | €434.83→€463.34 | buy | 20.98%Upside | Reiterated | 11/04/26 | ||
| Stephen Baxter | Wells Fargo | €421.46→€438.39 | buy | 14.46%Upside | Assigned | 10/27/26 | ||
| Ann Hynes | Mizuho Securities | €418.79→€436.61 | buy | 14.00%Upside | Reiterated | 10/23/26 | ||
| Ryan Langston | TD Cowen | €414.33→€441.06 | buy | 15.16%Upside | Reiterated | 10/23/26 | ||
| Kevin Fischbeck | Bank of America Securities | €445.52 | buy | 16.32%Upside | Assigned | 10/22/26 | ||
| Andrew Mok CFA | Barclays | €417.90→€420.57 | buy | 9.81%Upside | Reiterated | 10/22/26 | ||
| Michael Ha | Robert W. Baird | €350.18→€361.76 | hold | -5.55%Downside | Reiterated | 10/22/26 | ||
| Erin Wright | Morgan Stanley | €359.98→€400.08 | hold | 4.46%Upside | Reiterated | 10/22/26 | ||
| A.J. Rice | UBS | €409.88→€466.01 | buy | 21.67%Upside | Assigned | 10/22/26 | ||
| David S Macdonald | Truist Financial | €423.24→€445.52 | buy | 16.32%Upside | Reiterated | 10/22/26 | ||
| Scott Fidel | Goldman Sachs | €351.96→€401.86 | hold | 4.92%Upside | Reiterated | 10/22/26 | ||
| Jason Cassorla | Guggenheim | €409.88→€432.15 | buy | 12.83%Upside | Reiterated | 10/21/26 | ||
| Ben Hendrix | RBC Capital | €377.80→€405.42 | hold | 5.85%Upside | Reiterated | 10/21/26 | ||
| David Toung | Argus Research | ― | hold | ― | Reiterated | 08/20/26 | ||
| Whit Mayo | Leerink Partners | €324.34→€351.96 | hold | -8.10%Downside | Reiterated | 07/17/26 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| Lance WilkesBernstein | BuyReiterated€434.83→€463.34 | 11/04/26 | 20.98%Upside | ||
| Stephen BaxterWells Fargo | BuyAssigned€421.46→€438.39 | 10/27/26 | 14.46%Upside | ||
| Ann HynesMizuho Securities | BuyReiterated€418.79→€436.61 | 10/23/26 | 14.00%Upside | ||
| Ryan LangstonTD Cowen | BuyReiterated€414.33→€441.06 | 10/23/26 | 15.16%Upside | ||
| Kevin FischbeckBank of America Securities | BuyAssigned€445.52 | 10/22/26 | 16.32%Upside | ||
| Andrew Mok CFABarclays | BuyReiterated€417.90→€420.57 | 10/22/26 | 9.81%Upside | ||
| Michael HaRobert W. Baird | HoldReiterated€350.18→€361.76 | 10/22/26 | -5.55%Downside | ||
| Erin WrightMorgan Stanley | HoldReiterated€359.98→€400.08 | 10/22/26 | 4.46%Upside | ||
| A.J. RiceUBS | BuyAssigned€409.88→€466.01 | 10/22/26 | 21.67%Upside | ||
| David S MacdonaldTruist Financial | BuyReiterated€423.24→€445.52 | 10/22/26 | 16.32%Upside | ||
| Scott FidelGoldman Sachs | HoldReiterated€351.96→€401.86 | 10/22/26 | 4.92%Upside | ||
| Jason CassorlaGuggenheim | BuyReiterated€409.88→€432.15 | 10/21/26 | 12.83%Upside | ||
| Ben HendrixRBC Capital | HoldReiterated€377.80→€405.42 | 10/21/26 | 5.85%Upside | ||
| David ToungArgus Research | HoldReiterated | 08/20/26 | ― | ||
| Whit MayoLeerink Partners | HoldReiterated€324.34→€351.96 | 07/17/26 | -8.10%Downside |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Elevance Health
3 Months
Success Rate13/19 ratings generated profit
68%
Average Return
+0.98%
Copying Andrew Mok CFA's trades and holding each position for 3 Months would result in 68.42% of your transactions generating a profit, with an average return of +0.98% per trade.
1 Year
Success Rate14/18 ratings generated profit
78%
Average Return
+15.86%
Copying George Hill's trades and holding each position for 1 Year would result in 77.78% of your transactions generating a profit, with an average return of +15.86% per trade.
2 Years
Success Rate27/30 ratings generated profit
90%
Average Return
+35.53%
Copying A.J. Rice's trades and holding each position for 2 Years would result in 90.00% of your transactions generating a profit, with an average return of +35.53% per trade.
A58 Analyst Recommendation Trends
| Rating | Jul 26 | Aug 26 | Sep 26 | Oct 26 | Nov 26 |
|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 |
| Buy | 27 | 21 | 20 | 20 | 19 |
| Hold | 9 | 9 | 8 | 6 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 36 | 30 | 28 | 26 | 24 |
In the current month, A58 has received 19 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. A58 average Analyst price target in the past 3 months is 427.56.
A58 Financial Forecast
High€2.89
Consensus€1.87
Low€1.47
A58 Earnings Forecast
Next quarter’s earnings estimate for A58 is EUR 1.87 with a range of EUR 1.47 to EUR 2.89. The previous quarter’s EPS was EUR 6.28. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
High€46.7B
Consensus€44.4B
Low€42.3B
A58 Sales Forecast
Next quarter’s sales forecast for A58 is EUR 44.39B with a range of EUR 42.27B to EUR 46.74B. The previous quarter’s sales results were EUR 46.23B. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
A58 Stock Forecast FAQ
What is DE:A58’s average 12-month price target, according to analysts?
Based on analyst ratings, Elevance Health’s 12-month average price target is €427.56.
What is DE:A58’s upside potential, based on the analysts’ average price target?
Elevance Health has 11.64% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Elevance Health a Buy, Sell or Hold?
Elevance Health has a consensus rating of Moderate Buy, which is based on 9 buy ratings, 5 hold ratings and 0 sell ratings.
What is Elevance Health’s share price target?
The average share price target for Elevance Health is €427.56. This is based on 14 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is €466.01, and the lowest forecast is €361.76. The average share price target represents a 11.64% increase from the current price of €383.
What do analysts say about Elevance Health?
Elevance Health’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 14 Wall Street analysts.
How can I buy shares of Elevance Health?
To buy shares of DE:A58, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
